The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
Abstract
Therapeutic cancer vaccines are a heterogeneous group of complex biologics with distinctly different clinical characteristics than cytotoxic agents. The current clinical development paradigm used for oncology drug development is based on criteria developed for cytotoxic agents. More flexible and focused developmental guidelines are needed to address the unique characteristics of therapeutic cancer vaccines. Over the course of 1 year, the Cancer Vaccine Clinical Trial Working Group, representing academia and the pharmaceutical and biotechnology industries with participation from the US Food and Drug Administration, defined in a consensus process the cornerstones of a new clinical development paradigm for cancer vaccines and related biologics. Four major topics were addressed: (1) end points for clinical trials, (2) trial designs and statistical methods, (3) technical and developmental challenges, and (4) combination therapy. The proposed paradigm suggests therapeutic cancer vaccines to be investigated in 2 general types of clinical studies: proof-of-principle trials and efficacy trials. Proof-of-principle trials, which introduce a novel cancer vaccine into humans, should include a minimum of 20 or more patients in a homogenous, well-defined population in an adjuvant setting or without rapidly progressive disease in a metastatic setting to allow vaccines adequate time to induce biologic activity and should incorporate immune and molecular markers. Objectives should include initiation of a safety database, determination of dose and schedule, and demonstration of biologic activity as proof-of-principle. Biologic activity is defined as any effect of the vaccine on the target disease or host immune system using biologic markers as study end points, for example, clinical, molecular, or immune response. Immune response is demonstrated if determined in 2 separate, established and reproducible assays at 2 consecutive follow-up time points after the baseline assessment. If proof-of-principle trials show such immune response, or other biologic or clinical activity, efficacy trials may be initiated. If none of these end points is met, the clinical development plan should be reevaluated to decide if further development is warranted. Efficacy trials formally establish clinical benefit either directly or through a surrogate and are encouraged to be randomized studies. This is in contrast to single-arm phase 2 trials used for cytotoxic agents, which often use tumor response rate as the primary end point and historical controls as a comparator. Efficacy trials may use prospectively planned adaptive designs to expand from randomized phase 2 into phase 3 studies if well-defined trigger-point criteria are met, but the cost of incorporating such design elements should be carefully evaluated. Efficacy trials can also be exploratory randomized phase 2 trials or conventional phase 3 trials. In addition, conventional clinical end points can be adjusted to account for biologic features of cancer vaccines. The concept of efficacy trials allows for an early assessment of vaccine efficacy based on credible prospective data. This 2-phase developmental paradigm supports a more flexible, expeditious, and focused clinical developmental process with early and informed decision making. In addition, this report addresses clinical development challenges and issues for combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Randomized phase II clinical trials.
Simon, R. M., Wittes, R. E., & Ellenberg, S. S. (1985) · PubMed · Cited by 482
Keilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200203000-00001 · Cited by 298
Self-citationCurrent Developments in Cancer Vaccines and Cellular Immunotherapy
Ribas, A., Butterfield, L. H., Glaspy, J. A., & Economou, J. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.041 · Cited by 295
Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia
Hughes, T., & Branford, S. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.01.008 · Cited by 158
A perfect correlate does not a surrogate make
Baker, S. G., & Kramer, B. S. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-16 · Cited by 155
Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®
Sondak, V. K., & Sosman, J. A. (2003) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.004 · Cited by 122
Enumerating Antigen-Specific T-Cell Responses in Peripheral Blood
Hobeika, A. C., Morse, M. A., Osada, T., Ghanayem, M., Niedzwiecki, D., Barrier, R. C., Lyerly, H. K., & Clay, T. M. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200501000-00008 · Cited by 72
Workshop on Cancer Biometrics: Identifying Biomarkers and Surrogates of Cancer in Patients
Lotze, M. T., Wang, E., Marincola, F. M., Hanna, N., Bugelski, P. J., Burns, C. A., Coukos, G., Damle, N. K., Godfrey, T. E., Howell, W. M., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000154251.20125.2e · Cited by 32
Overview of therapeutic vaccination approaches for cancer
Berinstein, N. L. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00231-8 · Cited by 28
Cited by
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Self-citationiRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Astruc, D., Boisselier, E., & Ornelas, C. (2010) · Chemical Reviews · doi:10.1021/cr900327d · Cited by 1,844
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Self-citation
Metadata
- Authors
- Hoos, A., Parmiani, G., Hege, K., Sznol, M., Loibner, H., Eggermont, A., Urba, W., Blumenstein, B., Sacks, N., Keilholz, U., & Nichol, G.
- Venue
- Journal of Immunotherapy
- Published
- 2007-01
- Volume
- 30
- Issue
- 1
- Pages
- 1-15
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W2028697741
- Cited by
- 270
- References
- 10
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Clinical Development Paradigm for Cancer Vaccines and Related Biologics. https://app.cochat.ai/papers/10.1097/01.cji.0000211341.88835.ae
- The paper
- Hoos, A., Parmiani, G., Hege, K., Sznol, M., Loibner, H., Eggermont, A., Urba, W., Blumenstein, B., Sacks, N., Keilholz, U., & Nichol, G. (2007). A Clinical Development Paradigm for Cancer Vaccines and Related Biologics. Journal of Immunotherapy. https://doi.org/10.1097/01.cji.0000211341.88835.ae
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.